XML 12 R4.htm IDEA: XBRL DOCUMENT v3.22.1
CONSOLIDATED STATEMENTS OF OPERATIONS - USD ($)
12 Months Ended
Dec. 31, 2021
Dec. 31, 2020
CONSOLIDATED STATEMENTS OF OPERATIONS [Abstract]    
Revenue $ 1,061,000 $ 3,173,000
Costs and expenses:    
Patient expenses 86,000 361,000
Selling, general and administrative 1,064,000 1,197,000
Total 1,150,000 1,558,000
Operating (loss) income (89,000) 1,615,000
Total other (expense) income    
Interest expense (3,000) (25,000)
Interest income 0 3,000
Interest income - sales-type sublease 8,000 72,000
Loss from investments in unconsolidated entities, net (470,000) (809,000)
Total other expense (465,000) (759,000)
(Loss) income before income taxes (554,000) 856,000
Income tax provision 120,000 323,000
Net (loss) income (674,000) 533,000
Net loss attributable to noncontrolling interests 47,000 0
Net (loss) income attributable to U.S. Neurosurgical Holdings, Inc. $ (627,000) $ 533,000
Basic net (loss) income per share attributable to U.S. Neurosurgical Holdings, Inc. (in dollars per share) $ (0.08) $ 0.07
Diluted net (loss) income per share attributable to U.S. Neurosurgical Holdings, Inc. (in dollars per share) $ (0.08) $ 0.07
Weighted average common shares outstanding, basic (in shares) 7,792,185 7,792,185
Weighted average common shares outstanding, diluted (in shares) 7,792,185 7,792,185